Retatrutide vs Tirzepatide
Compare separate trial programmes with explicit cross-trial limitations; tirzepatide has authorised products while retatrutide remains investigational.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Human evidence | Retatrutide now has peer-reviewed Phase III human evidence in type 2 diabetes (TRANSCEND-T2D-1), alongside earlier randomized Phase II obesity and MASLD data. Obesity Phase III results are also emerging, but published and sponsor-reported evidence should be kept distinct. | Large Phase III obesity evidence shows substantial weight loss. SURMOUNT-OSA additionally demonstrated large reductions in sleep-apnea severity in adults with obesity and moderate-to-severe OSA. |
| Research focus | Obesity, weight management, metabolic disease | Type 2 diabetes, obesity, weight management |
| Regulatory status | Not FDA-approved as of this review; FDA states retatrutide has not been found safe and effective for any condition and cannot be used in US compounding. | Tirzepatide is authorised in licensed products such as Mounjaro for type 2 diabetes and adult weight management in the EU; authorization is product- and jurisdiction-specific. |
| Route / formulation | Evidence applies to trial-grade retatrutide, not to unverified research-market vials or pens. | Unverified research-market material or non-authorised pens are not equivalent to licensed tirzepatide medicines merely because the active-ingredient name matches. |
Why these are compared
These compounds appear in the weight & body composition evidence landscape, but they are not interchangeable. Retatrutide is tri-agonist peptide (gip/glp-1/glucagon receptor agonist) studied in obesity, weight management, metabolic disease; Tirzepatide is gip/glp-1 receptor agonist peptide studied in type 2 diabetes, obesity, weight management. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Retatrutide: Multiple Phase 3 human trials; investigational.
Tirzepatide: Strong Phase III / approved-product evidence across multiple indication-specific outcomes.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head outcome trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.